Profound Medical Corp (PROF) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Profound Medical Corp stock (PROF) is currently trading at $5.82. Profound Medical Corp PS ratio (Price-to-Sales) is 12.17. Analyst consensus price target for PROF is $11.90. WallStSmart rates PROF as Sell.
- PROF PE ratio analysis and historical PE chart
- PROF PS ratio (Price-to-Sales) history and trend
- PROF intrinsic value — DCF, Graham Number, EPV models
- PROF stock price prediction 2025 2026 2027 2028 2029 2030
- PROF fair value vs current price
- PROF insider transactions and insider buying
- Is PROF undervalued or overvalued?
- Profound Medical Corp financial analysis — revenue, earnings, cash flow
- PROF Piotroski F-Score and Altman Z-Score
- PROF analyst price target and Smart Rating
Profound Medical Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Profound Medical Corp (PROF) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Profound Medical Corp (PROF) Key Strengths (1)
Revenue surging 43.10% year-over-year
Supporting Valuation Data
Profound Medical Corp (PROF) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 45.42%
Supporting Valuation Data
Profound Medical Corp (PROF) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 43.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (12.17), Price/Book (2.76) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -67.10%, Operating Margin at -123.30%, Profit Margin at -264.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -67.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 43.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PROF Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PROF's Price-to-Sales ratio of 12.17x sits near its historical average of 14.16x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 37% below its historical high of 19.32x set in Mar 2026, and 5% above its historical low of 11.63x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~19.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Profound Medical Corp (PROF) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Profound Medical Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 16M with 43% growth year-over-year. The company is currently unprofitable, posting a -264.4% profit margin.
Key Findings
Revenue growing at 43% YoY, reaching 16M. This pace significantly outperforms most MEDICAL DEVICES peers.
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 25M in cash.
The company is unprofitable with a -264.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Profound Medical Corp maintain 43%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Profound Medical Corp.
Bottom Line
Profound Medical Corp is a high-conviction growth story with revenue accelerating at 43% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -264.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:00:56 AM
About Profound Medical Corp(PROF)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Profound Medical Corp. The company is headquartered in Mississauga, Canada.